Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents

摘要: Essentials The efficacy of systemic antifibrinolytics for hemophilic non-mucosal bleeding is undetermined. effect systemically inhibiting fibrinolysis in mice and rats was explored. Neither nor the response to factor treatment improved after fibrinolysis. phenotype hemophilia A appears largely unaffected by SUMMARY Background Fibrinolysis may exacerbate patients with (HA). Accordingly, have been used help maintain hemostatic control. Although antifibrinolytic drugs proven be effective mucosal bleeds oral cavity, their tissues remain an open question significant clinical interest. Objective To determine whether improves outcome tail vein transection (TVT) models, a standard ex vivo clotting/fibrinolysis assay can as predictive surrogate in vivo efficacy. Methods highly sensitive TVT model employed rodents suppressed fibrinolytic system examine on tissue. In mice, induced congenital models were combined attenuation achieved either genetically or pharmacologically (tranexamic acid [TXA]). rats, followed whole blood rotational thromboelastometry evaluation same animals gauge value such assays. Results beneficial TXA therapy observed could not confirmed rats. Furthermore, neither intravenously administered knockout genes encoding plasminogen tissue-type activator markedly mice. Conclusions findings here suggest that inhibition limiting HA tissues.